Larisa Miller

A Novel PEGylated Interferon Beta‐1a for Multiple Sclerosis: Safety, Pharmacology, and Biology

Xiao Hu, Larisa Miller, Sandra Richman et al. · The Journal of Clinical Pharmacology · 2011 · 122 citations

Long‐Term Safety and Efficacy of Eculizumab in Aquaporin‐4 <scp>IgG‐Positive NMOSD</scp>

Dean M. Wingerchuk, Kazuo Fujihara, Jacqueline Palace et al. · Annals of Neurology · 2021 · 91 citations · Full text

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

Sean J. Pittock, Kazuo Fujihara, Jacqueline Palace et al. · Multiple Sclerosis Journal · 2021 · 75 citations · Full text

Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial

Jacqueline Palace, Dean M. Wingerchuk, Kazuo Fujihara et al. · Multiple Sclerosis and Related Disorders · 2020 · 37 citations · Full text

Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension

Ho Jin Kim, Ichiro Nakashima, Shanthi Viswanathan et al. · Multiple Sclerosis and Related Disorders · 2021 · 11 citations · Full text